Skye Share Price

Skye Share Price

NASDAQ: SKYE | Micro Cap | Healthcare
$1.01
+0.00 (0.00%) Last updated on 18 Nov, 2026 | 22:23 IST
  • Performance
  • Chart
  • Fundamentals
  • Profit & Loss
  • Balance Sheet
  • Cash Flow
  • Corporate Actions
  • About
  • Price history
  • FAQs

Skye Stock Performance

Open
N/A
Prev. Close
$1.01
Circuit Range
N/A
Day Range
N/A
Year Range
$0.28 - $2.13
Volume
N/A
Average Traded
N/A

Skye Share Price Chart

Line chart of the Skye price trend over the selected period. The price rose overall, ranging from 1.01 to 1.03, ending at 1.01.
$0.00$0.00
L
Show Current Price
H

Skye Stock Fundamentals & Key Indicators

Market Cap
$40.06M
PE Ratio (TTM)
N/A
Dividend Yield
0.00%
EPS (TTM)
$-8.52
Revenue (TTM)
$0.00
Return On Equity (TTM)
-2768.93%
Profit Margin
N/A
Debt to Equity
0.03
Quarterly Earnings Growth YoY
100.48%

Skye Quarterly Profit & Loss

All figures in USD

ParticularsDec 2025Mar 2026Jun 2026Sep 2026
Revenue$0.00$0.00$0.00$0.00
Net Profit-$14.44-$12.51-$10.79$0.07
Net Profit MarginN/AN/AN/AN/A
Income ChangeN/A13.37%13.75%100.65%

Skye Annual Profit & Loss

All figures in USD

Particulars20242025
Revenue$0.00$0.00
Net Profit-$26.57-$55.92
Net Profit MarginN/AN/A
Income ChangeN/A-110.46%

Skye Balance Sheet

All figures in USD Million

Particulars20252024
Non Current Assets1.221.94
Current Assets27.0970.83
Total Assets28.3172.76
Non Current Liabilities0.080.27
Current Liabilities8.214.34
Total Liabilities8.294.61
Shareholders' Equity20.0268.15

Skye Cash Flow

Annually

All figures in USD Million

Particulars20252024
Operating-43.06-25.24
Investing-19.5-0.25
Financing0.0383.56

Corporate Actions

Split
Ex-date: 24 Aug 2026

Split
Ex-date: 08 Sep 2023

About Skye

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Skye Historical Returns

Share price history by day, with open and close prices and the day's change
MonthOpenCloseChange %
Nov 2026
$1.33
$1.01
-23.48%
Oct 2026
$1.56
$1.32
-19.51%
Sep 2026
$1.78
$1.64
-18.37%
Aug 2026
$0.57
$2.01
+242.25%
Jul 2026
$0.68
$0.59
-12.52%
Jun 2026
$0.79
$0.67
-13.42%
May 2026
$0.79
$0.78
-12.82%
Apr 2026
$0.68
$0.89
+47.92%
Mar 2026
$0.77
$0.60
-19.11%
Feb 2026
$0.92
$0.74
-26.44%
Jan 2026
$0.74
$1.01
+35.75%
Dec 2025
$1.25
$0.74
-43.85%

Skye Share Price FAQs